Artikel ; Online: Antiangiogenic therapies for advanced hepatocellular carcinoma.
2013 Band 18, Heft 4, Seite(n) 430–438
Abstract: Hepatocellular carcinoma (HCC) is a significant cause of death worldwide. HCC is a highly vascular tumor, and proangiogenic cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor ... ...
Abstract | Hepatocellular carcinoma (HCC) is a significant cause of death worldwide. HCC is a highly vascular tumor, and proangiogenic cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor may play crucial roles in this disease. Sorafenib, a multikinase inhibitor that blocks VEGF and PDGF signaling, was the first systemic therapy to demonstrate improved survival in patients with advanced HCC. Several other drugs targeting VEGF are in development. Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed. |
---|---|
Mesh-Begriff(e) | Angiogenesis Inhibitors/genetics ; Angiogenesis Inhibitors/therapeutic use ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/pathology ; Fibroblast Growth Factors/genetics ; Fibroblast Growth Factors/therapeutic use ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/genetics ; Liver Neoplasms/pathology ; Molecular Targeted Therapy ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/genetics ; Neovascularization, Pathologic/pathology ; Niacinamide/analogs & derivatives ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Platelet-Derived Growth Factor/genetics ; Platelet-Derived Growth Factor/therapeutic use ; Sorafenib ; Vascular Endothelial Growth Factor A/genetics ; Vascular Endothelial Growth Factor A/metabolism |
Chemische Substanzen | Angiogenesis Inhibitors ; Phenylurea Compounds ; Platelet-Derived Growth Factor ; Vascular Endothelial Growth Factor A ; Niacinamide (25X51I8RD4) ; Fibroblast Growth Factors (62031-54-3) ; Sorafenib (9ZOQ3TZI87) |
Sprache | Englisch |
Erscheinungsdatum | 2013-04-10 |
Erscheinungsland | United States |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 1409038-7 |
ISSN | 1549-490X ; 1083-7159 |
ISSN (online) | 1549-490X |
ISSN | 1083-7159 |
DOI | 10.1634/theoncologist.2012-0388 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 4845: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 494: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.